Key Highlights:
- Sunflower Therapeutics announced the sale and installation of multiple Daisy Petal Perfusion Bioreactor System units at Serum Institute of India in Pune. The deployment marks the largest installation of the Daisy Petal system to date and supports commercial-scale perfusion fermentation within GMP manufacturing space.
- The Daisy Petal Perfusion Bioreactor System uses a single-use stirred tank reactor with an in-vessel cell retention device that enables continuous perfusion fermentation. Compared with traditional fed-batch processes, the system can deliver 5–10x higher space-time yield, enabling faster and more efficient production of proteins used in vaccines and biologics.
- Integrated with Sunflower’s GMP-compliant software suite (HelianthOS, Nursery, and Harvest) the platform supports automated fermentation, simplified process development, and secure data management, helping manufacturers scale protein production while improving efficiency and accessibility of vaccines globally.
Implications:
The large-scale Daisy Petal deployment at Serum Institute signals a meaningful shift from traditional fed-batch to perfusion-based biomanufacturing in vaccines, showcasing perfusion as a practical option for high-volume, commercial GMP use rather than just development-scale experimentation.
By combining single-use, high–space-time-yield bioreactors with GMP-compliant, automated software, Sunflower lowers the operational and expertise barriers for running continuous processes—potentially shortening tech-transfer timelines and enabling faster response to surge vaccine demand or new pathogen outbreaks.
If the installation delivers the expected gains in productivity and footprint efficiency, it could encourage broader adoption of similar perfusion platforms across emerging markets, gradually reshaping cost structures and capacity planning for both vaccines and other biologics.
Source: Businesswire | Image: Sunflower therapeutics
No Comment! Be the first one.